MyShare
Key factors
| sym | CHMA |
| exch | US |
| MCap | 237.81M |
| Beta | 1.256 |
| EPS | -1.57 |
| Div date | 0000-00-00 |
Yesterday
| sym | CHMA |
| exch | US |
| close | 3.76 |
| 50 Day MA | 4.354 |
| 200 Day MA | 3.864 |
| Target Price | 9.1 |
| Market Cap Mln | 237.81 |
Share statistics
| Shares Outstanding | 63.24M |
| Shares Float | 33.80M |
| Percent Institutions | 76.11 |
| PercentInsiders | 0.581 |
| SharesShort | 756.01K |
| Short Ratio | 0.62 |
| Shares Short Prior Month | 849.92K |
| Short Percent | 2.239 |
Income
| Revenue TTM | 3030.0K |
| Revenue Per Share TTM | 0.053 |
| Gross Profit TTM | 1045.0K |
| EBITDA | -33.1M |
| Diluted Eps TTM | -1.57 |
earning
| Operating Margin TTM | -24.0 |
| EPS Estimate Current Quarter | -0.31 |
| EPS Estimate Current Year | -1.27 |
| EPS Estimate Next Quarter | -0.31 |
| EPS Estimate Next Year | -0.71 |
| Earnings Share | -1.57 |
Dividend
| Dividend Date | 0000-00-00 |
| Last Split Date | 0000-00-00 |
business
| Enterprise Value Revenue | 52.43 |
| Book Value /share | 1.084 |
| Price Book MRQ | 3.793 |
| Price Sales TTM | 71.22 |
| ReturnOnAssetsTTM | -0.37 |
| ReturnOnEquityTTM | -1.33 |
Sector
| Gic Group | Pharmaceuticals, Biotechnology & Life Sciences |
| Gic Industry | Pharmaceuticals |
| Gic Sector | Health Care |
| Gic Sub Industry | Pharmaceuticals |
| Industry | Biotechnology |
| Sector | Healthcare |
Codes
| ISIN | US16706W1027 |
| CIK | 1339469 |
| Code | CHMA |
| CUSIP | 16706W102 |
| Employer Id Number | 76-0722250 |
| CountryISO | US |
| Currency Code | USD |
| Currency Name | US Dollar |
| Exchange | NASDAQ |
| Currency Symbol | $ |
fund
| Type | Common Stock |
| UpdatedAt | 2021-11-14 |
| is Delisted | 1 |
| Delisted Date | 2021-09-15 |
| Home Category | Domestic |
info
| Fiscal Year End | December |
| Full Time Employees | 84.0 |
| IPODate | 2015-07-16 |
| International Domestic | Domestic |
| MostRecent Quarter | 2021-03-31 |
Contact
| Name | Chiasma Inc |
| Address | Building C East, Needham, MA, United States, 02494 |
| Country Name | USA |
| Phone | 617 928 5300 |
| Web URL | www.chiasma.com |
| Logo URL | /img/logos/US/CHMA.png |
Chiasma, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing oral medications using transient permeability enhancer technology platform for the treatment of rare and serious chronic disease worldwide. The company offers MYCAPSSA, an oral octreotide capsule for the long-term maintenance treatment in acromegaly patients who have responded to and tolerated treatment with octreotide or lanreotide. It also develops MPOWERED, an oral octreotide capsule, which has completed Phase III clinical trials for the maintenance treatment of adult patients with acromegaly. Chiasma, Inc. was incorporated in 2001 and is headquartered in Needham, Massachusetts.